Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Pharmaceuticals Holding Co's EBIT per Share for the
three
months ended in Mar. 2026 was €0.09.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.38.
During the past 12 months, the average EBIT per Share Growth Rate of Shanghai Pharmaceuticals Holding Co was 1.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -0.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -2.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 5.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
STU:S1R'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26.6 Med: 11.4 Max: 71.2
Current: -0.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Shanghai Pharmaceuticals Holding Co was 71.20% per year. The lowest was -26.60% per year. And the median was 11.40% per year.
STU:S1R's 3-Year EBIT Growth Rate is ranked worse than 57.94% of 107
companies
in the Medical Distribution industry
Industry Median: 2.7
vs STU:S1R: -0.30
Shanghai Pharmaceuticals Holding Co (STU:S1R) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Shanghai Pharmaceuticals Holding Co EBIT per Share Related Terms
Shanghai Pharmaceuticals Holding Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (STU:S1R) has a EBIT per Share of €0.38 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 107 companies in the Medical Distribution industry, placing it in the top 57.9%.
Is Shanghai Pharmaceuticals Holding Co's EBIT per Share too high?
Shanghai Pharmaceuticals Holding Co's current EBIT per Share is €0.38. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 107 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #62 out of 107 companies for EBIT per Share. This places Shanghai Pharmaceuticals Holding Co in the lower half of its industry. The industry median EBIT per Share is 2.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 2.70, based on 107 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median EBIT per Share is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current EBIT per Share is €0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co (STU:S1R) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.48, compared to a current price of €1.27 — trading 14.2% below its estimated fair value. The current EBIT per Share is €0.38. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (STU:S1R), the current EBIT per Share is €0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (STU:S1R) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of €1.27 is trading 14.2% below its estimated GF Value™ of €1.48.
GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.
Key valuation signals for STU:S1R:
EBIT per Share: €0.38
GF Value™: €1.48 vs. price of €1.27 (14.2% below fair value)
No single metric tells the full story. See the STU:S1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
78GF Score
Get the complete analysis for STU:S1R
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S1R has been successfully added to your 
